The reduced transcriptional activity of TGF‐β1 and its type III receptor demonstrated in patients with heart failure may be a useful marker in clinical practice for assessing the progression of coronary artery disease towards the development of heart failure, as well as its decompensation and compensation. Here, TGFB1 is linked to heart failure.